Abstract:Background: Disease modifying treatments for dementia are only just surfacing, and their development is still significantly hindered by the lack of validated tools for identification of subjects with subclinical disease. Much interest has been taken in developing accessible non-invasive serum biomarkers of neurodegeneration. Recent studies have identified caspase-3-cleaved tau (Tau-C), and ADAM-10 cleaved tau (Tau-A) as possible markers of preclinical neurodegenerative disease. Objectives: To explore if serum levels of Tau-A and Tau-C change as a consequence of neurodegeneration. Design and setting: Cohort study with measurement of biomarkers and genome sequencing at baseline with follow-up after an average of 14 years. Participants: Postmenopausal Danish women from the Prospective Epidemiological Risk Factor (PERF) cohort (n=4968) Methods: Genotyping data was used to perform a Mendelian randomization analysis of serum levels of Tau-A and Tau-C in relation to a diagnosis of dementia at follow-up. A dementia diagnosis was defined as a composite of an all-cause dementia diagnosis derived from the Danish National Health registries, a self-reported diagnosis of dementia and/or cognitive test scores suggestive of dementia. Serum levels of Tau-A and Tau-C were measured blinded in samples from baseline in a CAP certified lab. The association with dementia was assessed using bi-directional one- and two- sample Mendelian randomization. Results: A lead single nucleotide polymorphism (SNP) was identified for Tau-A (rs10414043) and Tau-C (rs429358), respectively were identified. Both were located in the APOE/C1 cluster on chromosome 19. APOE and EPOC1 variants were associated with lower levels of Tau-A and Tau-C levels - effect size -0.13, 95%CI [-0.17 - -0.09] log2 (ng/mL), p=7.05e-11 for rs10414043 association with Tau-A and effect size -0.12, 95%CI [-0.15 - -0.08] log2 (ng/mL), p=2e-11 for rs429358 association with Tau-C. When incorporating genetic data from a larger genetic study we found that Alzheimer's disease was marginally associated with a decreased Tau-A and Tau-C levels (Odds Ratio 0.97, 95%CI [0.93 - 1.00]. No association was found in the forward Mendelian randomization analysis. Conclusions: By combining genotype data with serum measurements of the novel biomarkers Tau-A and Tau-C, we conclude that Tau-A and Tau-C levels change because of neurodegeneration. We also conclude that lower serum-values of the biomarkers are associated with the presence of genetic variants commonly found in individuals suffering from late-onset Alzheimer's Dementia. These findings add to the growing data pointing towards Tau-A and Tau-C as valuable biomarkers for neurodegeneration.

A genome-wide association study of longitudinal change in CSF tau among non-demented elderly

SNPs Associated with Cerebrospinal Fluid Phospho-Tau Levels Influence Rate of Decline in Alzheimer's Disease

Genome-wide Association Study Identifies CBFA2T3 Affecting the Rate of CSF Aβ42 Decline in Non-Demented Elders.

Genome-wide Association Study of Cerebrospinal Fluid Neurofilament Light Levels in Non-Demented Elders.

A Genome-Wide Association Study of Α-Synuclein Levels in Cerebrospinal Fluid

Validating Gwas-Identified Risk Loci for Alzheimer'S Disease in Han Chinese Populations

Genome-wide Association Study of Brain Tau Deposition As Measured by 18F-Flortaucipir Positron Emission Tomography Imaging.

An updated analysis of the association between CD2-associated protein gene rs9349407 polymorphism and Alzheimer's disease in Chinese population

Genome-wide Association Study of Hippocampal Atrophy Rate in Non-Demented Elders

Genome-wide Association Study Identifies APOE Locus Influencing Plasma P-Tau181 Levels

Genetic loci associated with Alzheimer's disease and cerebrospinal fluid biomarkers in a Finnish case-control cohort

A Genetic Validation of the Neurodegeneration Biomarkers Tau-A and Tau-C - A Mendelian Randomization Study

Genome-wide scan of Flortaucipir PET levels finds associated with cerebral tau deposition

Multivariate GWAS of Alzheimer's disease CSF biomarker profiles implies GRIN2D in synaptic functioning

Genome-wide Association Study Identifies MAPT Locus Influencing Human Plasma Tau Levels.

Association of Frontotemporal Dementia GWAS Loci with Late-Onset Alzheimer’s Disease in a Northern Han Chinese Population

Genome-wide meta-analysis for Alzheimer's disease cerebrospinal fluid biomarkers

Common Variant in PLD3 Influencing Cerebrospinal Fluid Total Tau Levels and Hippocampal Volumes in Mild Cognitive Impairment Patients from the ADNI Cohort

CFH Variants Affect Structural and Functional Brain Changes and Genetic Risk of Alzheimer’s Disease

Genome-Wide Association Study of Incident Dementia in a Community-Based Sample of Older Subjects

Genome-wide association study identifies CD1A associated with rate of increase in plasma neurofilament light in non-demented elders.